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Abstract Primary mediastinal large B cell lymphoma
(PMLBCL) is a subtype of diffuse large B cell lymphoma
arising in the mediastinum with distinctive clinical and
morphological features. Though diffuse large B cell
lymphoma is one of the most common non-Hodgkin
lymphoma associated with AIDS, there are no data
available regarding the association of HIV and PMLBCL.
We report here two cases of PMLBCL arising in AIDS
patients. In both cases, PMLBCL presented in a setting of
low CD4 T-cell count as rapidly enlarging mediastinal
mass. The morphologic and immunophenotypic findings
are characteristic of PMLBCL. One of the two patients, a
25-year-old woman who had localized disease and evidence
of Epstein–Barr virus in lymphoma cells, did not respond to
chemotherapy and died of disease progression 5 months
after diagnosis. The second patient, a 38-year-old male with
disseminated disease, responded to therapy and is disease-




The incidence of non-Hodgkin lymphoma (NHL) is 100–
200-fold higher in HIV-infected individuals than in the
general population. NHL is an AIDS-defining illness and in
3–5% of cases, the lymphoma is the initial manifestation of
AIDS [1]. The most common HIV-associated lymphomas
are diffuse large B cell lymphoma (DLBCL; often primary
in the central nervous system), Burkitt lymphoma, primary
effusion lymphoma, and plasmablastic lymphoma of the
oral cavity [2]. Primary mediastinal large B cell lymphoma
is a subtype of diffuse large B cell lymphoma arising in the
mediastinum with distinctive clinical, morphologic, and
genotypic features [3]. Most patients are young adult
females presenting with localized mediastinal mass and
symptoms often related to local effects of the large
mediastinal tumor such as superior vena cava syndrome.
DLBCL is one of the most common lymphomas in the
setting of HIV, but the incidence of PMLBCL in HIV is not
well established. Only one reported case of HIV-associated
PMLBCL has been found in the English literature [4]. We




A 25-year-old female presented to her physician with
1 week of worsening shortness of breath, cough, and chest
pain. She gave birth to her fourth child 5 weeks ago, and
her cough and shortness of birth was developed a few days
prior to delivery. She was diagnosed with HIV 1 year
before; however, she had no previous manifestation of
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Chicago, IL 60611, USAAIDS. She was on azathyoprine while pregnant. Her last
CD4 count was 152/μL and her LDH was 379. Chest
computed tomography (CT) revealed a 13.7×9.2-cm
superior mediastinal mass, multiple left pleural masses
ranging from 2.4–2.7 cm, a 1.6-cm left upper lobe lung
nodule, and bilateral pleural effusions (Fig. 1). She
underwent mediastinoscopic biopsy of the mass. Pathologic
examination showed varying degrees of fibrosis associated
with lymphoid infiltrate. The infiltrating cells were mostly
large with irregular and convoluted vesicular nuclei, 1–3
visible nucleoli, and moderately abundant cytoplasm. Many
cells showed prominent pink nucleoli. Small areas of
necrosis were present, and scattered mitotic activity was
seen. The tumor cells were CD45+, CD20+, CD23+,
partially CD30+, weak partial positive for Bcl-2 and Bcl-
6, and negative for CD3, CD5, CD10, CD15, CD21, and
ALK-1. EBER in situ hybridization was positive in
approximately 30% of the tumor cells (Fig. 2). Flow
cytomeric immunophenotyping showed a decreased CD4/
CD8 ratio of 0.3 and evidence of an abnormal B cell
population with expression of CD19 and CD20 but lack of
surface immunoglobulin light chain expression. A diagno-
sis of primary mediastinal diffuse large B-cell lymphoma
was rendered. Subsequent staging bone marrow biopsy did
not show involvement by lymphoma. Lumbar puncture and
a magnetic resonance imaging of the brain showed no
evidence of central nervous system involvement of lym-
phoma. The patient was treated with 3 cycles EPOCH
chemotherapy. Her symptoms initially improved; however,
after the third cycle, her disease progressed and the
treatment was changed to VP-16, Ifosfamide, and Ara-C
with concurrent mesna. Her symptoms continued worsen-
ing and she died of respiratory failure 5 months after the
diagnosis of the lymphoma.
Case 2
A 38-year-old male with history of HIV for 7 years and no
prior AIDS-defining illness presented with complaints of
progressive shortness of breath for 10 days and one episode
of fever 2 weeks prior to the onset of his symptoms. He had
night sweats for about 3 years, but he denied weight loss,
cough, or hemoptysis. On admission, his laboratory values
showed a CD4 count of 140/μL and a markedly elevated
LDH value of 886. Imaging studies of the chest revealed an
abnormal cardiomediastinal silhouette caused by a large
left-sided mediastinal mass extending within the superior
hemithorax medially. In addition, large left-sided pleural
effusion was present, and several nodular opacities were
noted in the left lung (Fig. 3). The patient was admitted,
and highly active antiretroviral therapy (HAART) was
started. Subsequently, direct biopsy of the mass was
performed by mediastinoscopy. The biopsy showed a
variably dense lymphoid infiltrate composed of large
lymphoid cells with abundant pale cytoplasm, pleomorphic
nuclei which focal clusters, and rounded nests surrounded
by delicate fibrous bands. Frequent mitoses, including
atypical mitotic forms, were present. Immunohistochemis-
try showed that the tumor cells were positive for CD45,
CD20, CD30, Bcl-2, and Bcl-6, were focally positive for
CD23, and were negative for cytokeratin, CD3, CD10,
CD15, and ALK-1. EBER in situ hybridization was mostly
negative, with only very rare scattered positively staining
cells (Fig. 4). Flow cytometric analysis showed a popula-
tion of T lymphocytes with a CD4/CD8 ratio of 1.4, but no
discrete CD19+ or CD20+ B cell cluster was identified. The
overall findings were diagnostic of a primary mediastinal
large B cell lymphoma. A bone marrow biopsy showed
hypercellular bone marrow with no evidence of lymphoma.
A positron emission tomography scan, however, revealed
multifocal extranodal thoracic, both nodal and extranodal
abdominal, and possible acetabular involvement by the
lymphoma. The patient was treated with steroids followed
by combination chemotherapy with Rituxan-hyperCVAD/
intrathecal metothrexate in addition to HAART and antimi-
crobial medication including bactrim, acyclovir, and diflu-
can. After 2 cycles of therapy, the mediastinal mass
decreased in size, and the LDH level dropped to 168. The
patient responded well to the therapy and after 9 months of
follow-up, he is without detectable disease.
Discussion
The World Health Organization classification of hemato-
poietic malignancies recognizes AIDS-associated lympho-
mas as a specific category to acknowledge the significant
impact of HIV on the pathophysiology and prognosis of
Fig. 1 Chest CT of Case 1 reveals a 13.7×9.2-cm superior
mediastinal mass, multiple left pleural masses ranging from 2.4–
2.7 cm, a 1.6-cm left upper lobe lung nodule, and bilateral pleural
effusions
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to lymphoma genesis are complex and include chronic
antigen stimulation, genetic abnormalities, cytokine dysre-
gulation, and the role of herpes viruses: Epstein–Barr virus
(EBV) and Kaposi Sarcoma Human Virus (KSHV, HHV8)
[5]. The overall survival of patients with HIV-related NHLs
is inferior compared to HIV-negative patients, and in HIV,
the majority of patients present with widespread disease
and with higher risk for central nervous system involve-
ment. The introduction of HAART extended the lifespan of
AIDS patients and some studies indicated a decrease of the
incidence of lymphomas in AIDS since widespread
availability of HAART [6]. The combination of HAART
with aggressive chemotherapy, such as CHOP, not only is
tolerable and effective treatment in patients with HIV and
NHL but the initial good response to HAART is also
associated with higher complete response rates to the
chemotherapy (77% response to CHOP versus 50% in
nonresponders) [7]. The association between HIV and
classical Hodgkin lymphoma is less clear, and, unexpect-
edly, the incidence of Hodgkin lymphoma in AIDS has
increased since HAART was introduced [8]. Of note, HIV-
related Hodgkin lymphoma is associated with EBV in
nearly all cases [9], and it has been postulated that the EBV-
encoded latent membrane protein (LMP1; which is func-
tionally homologous to activated CD40), is essential to the
antiapoptotic phenotype of the Reed–Sternberg cells,
replacing the CD40/CD40 ligand interaction by CD4+ T
cells, which are decreased in AIDS [10].
Though diffuse large B cell lymphoma is one of the most
common NHL associated with AIDS, there are virtually no
data available about the association of HIV and PMLBCL.
So far, only one case of PMLBCL has been described in the
literature in the setting of AIDS [4]. This patient, a 29-year-
old woman with 12 years of history of HIV infection
without prior AIDS-defining illness, presented with fever,
night sweats, cough, and a CD4 count of 316/μL. HAART
therapy was initiated but had to be discontinued within a
Fig. 3 Chest X-ray of Case 2 shows an abnormal cardiomediastinal
silhouette caused by a large left-sided mediastinal mass extending
within the superior hemithorax medially. In addition, large left-sided
pleural effusion is present, and several nodular opacities are noted in
the left lung
Fig. 2 Pathologic examination
of Case 1 shows varying degrees
of compartmentalizing fibrosis
associated with lymphocytic in-
filtrate. The infiltrating cells are
mostly large with irregular and
convoluted vesicular nuclei, 1–3
visible nucleoli, and moderate
cytoplasm. The tumor cells are
strongly positive for CD20.
EBER in situ hybridization is
positive in approximately 30%
of the tumor cells
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drome. Biopsies via mediastinotomy established the diag-
nosis of PMLBCL, with no evidence of extrathoracic
disease upon staging. Chemotherapy with CHOP and
granulocyte colony-stimulating factor was started; however,
6 days after the first cycle of treatment, the patient died
from neutropenic sepsis.
In our current report, the clinical presentation in Case 1
is classical in terms that the patient is a young woman who
presents with a mediastinal mass and her disease is
localized to the mediastinum (Table 1 summarizes the
clinical findings of Cases 1 and 2 in comparison to the case
reported by Milling et al.). This patient was known to have
HIV but because she was pregnant, she only received AZT
monotherapy and had very low CD4 T-cell count (152/μL)
at diagnosis. In contrast, the clinical presentation of Case 2
is unusual in several aspects. The patient is a male and in
addition to a large mediastinal mass, he has widespread
Table 1 Comparison of the clinical features of Case 1, Case 2, and the case reported by Milling et al. 2004
Case #1 Case #2 Case reported by
Millings et al. 2004
Age/sex 25/Female 38/Male 29/Female
Presentation Shortness of breath,
cough, chest pain




Duration of HIV+ status 1 year 7 years 12 years
Prior therapy for HIV Azathyoprine None None
CD4 count at presentation 152/μL 140/μL 316/μL
LDH at presentation 379 IU/L (high) 886 IU/L (high) 542 IU/L (high)
Stage of disease Stage IV Stage IV Not stated
Bone marrow involvement Negative Negative Negative
Extramediastinal involvement Pleural masses, pleural
effusions, left lung nodule




Therapy received HAART, 3 cycles of EPOCH then
VP-16, ifosfamide, ARA-C, mesna
HAART, 6 cycles of
Rituxan-Hyper CVAD
1 cycle of CHOP
and G-CSF
Outcome Death 5 months after diagnosis No detectable disease after
9 months follow-up
Death 6 days after
chemotherapy
Fig. 4 Microscopic sections of
Case 2 show dense lymphoid
infiltrate composed of large
lymphoid cells with abundant
pale cytoplasm, pleomorphic
nuclei which form clusters and
rounded nests surrounded by
delicate fibrous bands. Frequent
mitoses, including atypical
mitotic forms are present. By
immunohistochemistry, the tu-
mor cells are positive for CD20,
CD30, and Bcl-6. EBER in situ
hybridization was negative
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receive HAART therapy prior to his presentation and his
CD4 T-cell count was low (140/μL). Neither of the two
patients had evidence of bone marrow or central nervous
system involvement. The immunophenotype of the lym-
phoma cells of both cases is consistent with previously
described phenotype of PMLBCL: CD45+, CD20+,
CD23+, and partially CD30+. In Case 2, but not in Case
1, the lymphoma cells also express Bcl-6, a finding unusual
but not excluding the diagnosis of PMLBCL. An important
finding in Case 1 is the EBV positivity in approximately
30% of the lymphoma cells by EBER in situ hybridization.
The role of EBV in the pathogenesis of PMLBCL in the
immunocompetent host was previously dismissed. In one
study, only two cases were positive for EBV of 41
PMLBCL cases [11]; others reported complete absence of
EBV [12]. The previously reported case of PMLBCL in
HIV-infected patient also was negative for EBV with EBER
in situ hybridization [4]. In our case, it is not clear as to
what extent the EBV positivity contributes to lymphoma
pathogenesis or represents EBV infection acquired during
the course of disease. Yet, the finding of 30% EBER-
positive lymphoma cells is likely to be clinically signifi-
cant, since Park et al. recently reported that EBER
positivity of 20% or more in lymphoma cells in DLBCL
is associated with significantly poorer overall survival and
progression-free survival compared to EBV-negative
DLBCLs [13]. In the immunocompromised, such as AIDS
or post-transplant state, EBV infection even in a minority of
lymphoma cells might have significant impact on disease
pathogenesis and outcome. Since the molecular signature of
PMLBCL resembles that of classical Hodgkin lymphoma
[14], EBV infection might contribute to an anti-apoptotic
phenotype of the lymphoma cells with a similar mechanism
as observed in HIV-associated Hodgkin lymphoma. In our
patient with EBV-associated PMLBCL, despite the local-
ized nature of the lymphoma, the tumor continued to
progress during chemotherapy resulting in death of the
patient after 5 months of diagnosis. Unlike Case 1, Case 2
responded well to a combination of HAART and chemo-
therapy and improved rapidly, despite widespread disease at
diagnosis.
In summary, though increased incidence of PMLBCL
has not been established in AIDS due to the rarity of these
cases, PMLBCL occurs in HIV and appears to present in
the setting of low CD4 T-cell count as a rapidly growing
mediastinal mass. A good response to a combination of
HAART and chemotherapy can be obtained even in cases
with widespread disease. More cases are necessary to
characterize the relationship between PMLBCL and HIV
and to determine the impact of EBV infection on disease
pathogenesis and prognosis in the immunocompromised.
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